SBIR-STTR Award

Percutaneous system for energy transmission
Award last edited on: 4/24/02

Sponsored Program
SBIR
Awarding Agency
NIH : NHLBI
Total Award Amount
$50,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Adrian Kantrowitz

Company Information

L.VAD Technology Inc (AKA: CardioPlus Inc~ViaDerm LLC)

46701 North Commerce Center Drive
Plymouth, MI 48170
   (734) 233-3985
   info@viadermllc.com
   www.lvadtech.com
Location: Single
Congr. District: 06
County: Wayne

Phase I

Contract Number: 1R43HL031876-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1984
Phase I Amount
$50,000
A percutaneous access device (PAD) is an artificial aperture in the skin intended to establish a permanent passageway between the inside and the outside of the body without interfering with host homeostasis. PAD's have many potential uses and have been studied extensively in relation to permanently implanted prostheses that augment the action of the failing heart. Current cardiac assist systems depend on electrical or pneumatic power, which must be transmitted across or through the skin. As yet, however, a PAD that is reliable in long-term use has not been developed.To prevent infection, the major cause of PAD failure, the investigators postulate that PAD design must provide for (1) control of epidermal proliferation and migration in proximity to the implant, and (2) attenuation of local strain. A PAD hypothesized to meet these requirements is being studied in rats and swine. Its neck (the transcutaneous portion) is nanoporous; a Dacron velour-covered flange joined to the neck is placed subdermally. Before implantation, autologous fibroblasts are cultured onto the PAD neck, forming a multilayer coating. The results indicate that PAD's prepared in this way inhibit epithelial downgrowth, whereas uncoated implants fail as a result of epidermal migration and infection.The objective of this Phase I project is to transfer and extend to sheep (which increasingly are used for full-scale testing of cardiac assist systems) the methods evolved in swine. Specific aims are to: (1) adapt techniques for in vitro fibroblast proliferation and coliagen production on the PAD neck to sheep cells-, 2 adapt surgical techniques for PAD implantation to sheep; and (3) develop a protocol for long-term evaluation in sheep of a functioning PAD transferring power to an implanted heart assist device.The long-range goal is to qualify a PAD and make it commercially available for clinical use in conjunction with a system for treatment of patients in severe, chronic left heart failure. In addition, availability of the PAD for sheep will facilitate its adoption for preclinical evaluation of various mechanical heart assist systems by others. This program will also lead to improved PAD's for other commercial applications such as vascular access for kidney dialysis and skeletal attachment of prosthetic limbs.National Heart, Lung, And Blood Institute

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----